| 000 | 01629 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517154555.0 | ||
| 264 | 0 | _c20180301 | |
| 008 | 201803s 0 0 eng d | ||
| 022 | _a1449-1907 | ||
| 024 | 7 |
_a10.7150/ijms.18784 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aYamagiwa, Satoshi | |
| 245 | 0 | 0 |
_aIncrease of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C. _h[electronic resource] |
| 260 |
_bInternational journal of medical sciences _c2017 |
||
| 300 |
_a403-411 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aB7-H1 Antigen _xblood |
| 650 | 0 | 4 |
_aCarcinoma, Hepatocellular _xblood |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xblood |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterferon-gamma _xadministration & dosage |
| 650 | 0 | 4 |
_aLiver Neoplasms _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOligopeptides _xadministration & dosage |
| 650 | 0 | 4 |
_aRibavirin _xadministration & dosage |
| 650 | 0 | 4 |
_aSimeprevir _xadministration & dosage |
| 700 | 1 | _aIshikawa, Toru | |
| 700 | 1 | _aWaguri, Nobuo | |
| 700 | 1 | _aSugitani, Soichi | |
| 700 | 1 | _aKamimura, Kenya | |
| 700 | 1 | _aTsuchiya, Atsunori | |
| 700 | 1 | _aTakamura, Masaaki | |
| 700 | 1 | _aKawai, Hirokazu | |
| 700 | 1 | _aTerai, Shuji | |
| 773 | 0 |
_tInternational journal of medical sciences _gvol. 14 _gno. 5 _gp. 403-411 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.7150/ijms.18784 _zAvailable from publisher's website |
| 999 |
_c27205833 _d27205833 |
||